Robots Revolutionize Antibiotic Discovery with 700 New Compounds

Researchers at the University of York have successfully utilized robotic technology to develop and test over 700 metal compounds in just one week. This innovative approach has led to the discovery of a promising new antibiotic capable of combating drug-resistant bacteria, a growing global health concern. The study highlights the potential of automated chemistry to expedite the discovery of urgently needed antibiotics as traditional methods struggle to keep pace with rising antimicrobial resistance.

The research, led by Dr. Angelo Frei, aims to address a critical gap in antibiotic development. Antimicrobial resistance currently claims more than one million lives annually worldwide, making the search for new drugs increasingly urgent. As conventional antibiotics lose effectiveness, even standard medical procedures, such as hip replacements and chemotherapy, risk becoming perilously unsafe.

Dr. Frei and his team opted to explore metal-based compounds rather than adjusting existing drug classes. This decision marks a significant shift in research direction, as metal-based antibiotics have often been overlooked due to concerns regarding toxicity and complexity. By integrating robotics with high-speed chemistry, the research team compressed months of labor-intensive work into a single week.

Speed and Efficiency in Antibiotic Discovery

Central to this breakthrough is an automated system that employs “click” chemistry, a technique that efficiently combines molecular building blocks. Dr. David Husbands, a postdoctoral researcher, played a key role in pairing nearly 200 different ligands with five distinct metals, resulting in the rapid synthesis of more than 700 unique metal complexes within a week.

Traditional antibiotic discovery processes are often slow, costly, and increasingly unappealing to pharmaceutical companies. The researchers argue that automation can significantly broaden the chemical landscape while reducing both time and labor costs. After synthesizing the compounds, the team screened them for antibacterial properties while ensuring minimal toxicity to human cells. Six candidates emerged as potential leads, with one compound—a novel iridium-based complex—demonstrating strong antibacterial activity against strains akin to MRSA, all while proving non-toxic to human cells.

This promising candidate exhibits a high therapeutic index, suggesting it could be a viable option for further development. The three-dimensional nature of metal-based compounds provides a distinct advantage over conventional flat, carbon-based molecules, potentially enabling them to evade existing resistance mechanisms.

Challenges and Future Directions

Dr. Frei emphasized the urgency of this work, stating, “The pipeline for new antibiotics has been running dry for decades. We have to think differently.” He added that the combination of innovative “click” chemistry with robotics allows for the exploration of vast, untapped areas of chemical space at unprecedented speed.

The findings challenge long-held beliefs regarding metal-based drugs. According to data from the Community for Open Antimicrobial Drug Discovery, metal complexes may exhibit a higher “hit rate” for antibacterial activity while maintaining lower toxicity compared to standard organic molecules.

The implications of this research extend beyond antibiotic discovery. The rapid-synthesis platform developed by the researchers could also be adapted for discovering new catalysts for industrial processes, showcasing its versatility beyond biomedical applications.

The team is currently focused on understanding the mechanisms by which the iridium compound attacks bacteria and plans to expand the robotic system to investigate other metals and potential applications further. The full findings of this pioneering study were published in Nature Communications in March 2024, marking a significant advancement in the quest for novel antibiotics amidst escalating global health challenges.